Published : Sep-2019
No. of Pages : 38
1.1 List of Tables
1.2 List of Figures
2 Axial Spondyloarthritis: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Base Scenario
3.4.3 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-AxSpA - Base Scenario
3.4.4 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Alternative Scenario
3.4.5 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-AxSpA - Alternative Scenario
3.4.6 Forecast Assumptions and Methods, HLA-B27 Seropositivity Among Diagnosed AS Patients
3.5 Epidemiological Forecast for AS and Nr-AxSpA (2018-2028) - Base Scenario
3.5.1 Diagnosed Prevalent Cases of AS
3.5.2 Diagnosed Prevalent Cases of Nr-AxSpA
3.6 Epidemiological Forecast for AS and Nr-AxSpA (2018-2028) - Alternative Scenario
3.6.1 Diagnosed Prevalent Cases of AS
3.6.2 Age-Specific Diagnosed Prevalent Cases of AS
3.6.3 Sex-Specific Diagnosed Prevalent Cases of AS
3.6.4 Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity
3.6.5 Diagnosed Prevalent Cases of Nr-AxSpA
3.6.6 Age-Specific Diagnosed Prevalent Cases of Nr-AxSpA
3.6.7 Sex-Specific Diagnosed Prevalent Cases of Nr-AxSpA
3.7 Discussion
3.7.1 Epidemiological Forecast Insight
3.7.2 Limitations of the Analysis
3.7.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 Primary Research - Prescriber Survey
4.3 Abbreviations
4.4 About the Authors
4.4.1 Epidemiologist
4.4.2 Reviewers
4.4.3 Global Director of Therapy Analysis and Epidemiology
4.4.4 Global Head and EVP of Healthcare Operations and Strategy
4.5 About GlobalData
4.6 Contact Us
4.7 Disclaimer
List of Tables
Table 1: Risk Factors and Comorbidities for AS
Table 2: High-Prescribing Physicians (KOL and non-KOLs) Surveyed, By Country
List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of AS, All Ages, Both Sexes, N, 2018 and 2028 - Base Scenario
Figure 2: 7MM, Diagnosed Prevalent Cases of Nr-AxSpA, All Ages, Both Sexes, N, 2018 and 2028 - Base Scenario
Figure 3: 7MM, Diagnosed Prevalence (%) of AxSpA, Both Sexes, Ages ?18 Years, 2008-2028 - Base Scenario
Figure 4: 7MM, Sources Used, Diagnosed Prevalent Cases of AS - Base Scenario
Figure 5: 7MM, Sources Used, Diagnosed Prevalent Cases of Nr-AxSpA - Base Scenario
Figure 6: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of AS - Alternative Scenario
Figure 7: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of Nr-AxSpA - Alternative Scenario
Figure 8: 7MM, Sources Used, HLA-B27 Seropositivity Data Among the Diagnosed Prevalent Cases of AS - Alternative Scenario
Figure 9: 7MM, Diagnosed Prevalent Cases of AS, Ages ?18 Years, Both Sexes, N, 2018 - Base Scenario
Figure 10: 7MM, Diagnosed Prevalent Cases of Nr-AxSpA, Ages ?18 Years, Both Sexes, N, 2018 - Base Scenario
Figure 11: 7MM, Diagnosed Prevalent Cases of AS, Ages ?18 Years, Both Sexes, N, 2018 - Alternative Scenario
Figure 12: 7MM, Age-Specific Diagnosed Prevalent Cases of AS, Both Sexes, N, 2018 - Alternative Scenario
Figure 13: 7MM, Sex-Specific Diagnosed Prevalent Cases of AS, Ages ?18 Years, N, 2018 - Alternative Scenario
Figure 14: 7MM, Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity, Ages ?18 Years, Both Sexes, N, 2018 - Alternative Scenario
Figure 15: 7MM, Diagnosed Prevalent Cases of Nr-AxSpA, Ages ?18 Years, Both Sexes, N, 2018 - Alternative Scenario
Figure 16: 7MM, Age-Specific Diagnosed Prevalent Cases of Nr-AxSpA, Both Sexes, N, 2018 - Alternative Scenario
Figure 17: 7MM, Sex-Specific Diagnosed Prevalent Cases of Nr-AxSpA, Ages ?18 Years, N, 2018 - Alternative Scenario
